Platform IP means Platform Know-How and Platform Patents.
Platform IP means all: (i) Collaboration Information and Inventions that are [***], and (ii) Patent Rights reciting, claiming, or covering such Collaboration Information and Inventions described in clause (i) that [***].
Platform IP means (a) Platform Claims and (b) Know-How that relates to the *** (y) relates specifically to ***).
Examples of Platform IP in a sentence
Neither this Agreement nor your use of Uber’s or our licensors’ company names, logos, products or service names, trademarks, service marks, trade dress, other indicia of ownership, or copyrights (“Uber Names, Marks, or Works”) or the Platform IP conveys or grants to you any rights in or related to the Platform IP, or related intellectual property rights, including Uber’s Names, Marks, or Works, except for the limited license granted above.
The Platform IP is provided for your internal business use only in respect of trading activity conducted by you as an employee of a customer of TP ICAP and for no other purpose and on a view-only and non-executable basis in object code form only, unless specifically authorised otherwise in writing by TP ICAP.
In this regard, the SER subscribes to the arguments and recommendations of the Innovation Platform (IP), laid down in the Knowledge Investment Agenda 2006-2016 (see: Dutch country report WP2).
You agree that you will not use Platform IP in any manner that may impair, damage, disable, interfere with or otherwise compromise Platform IP or anyone else’s use of Platform IP.
You agree to comply with all laws and regulations governing the downloading, installation and/or use of Platform IP.
More Definitions of Platform IP
Platform IP means (a) the Know-How Controlled by Pxxxxx that is necessary or useful for the practice of the Platform Technology, and (b) those Patents Controlled by Pxxxxx directed to the Platform Technology as set forth in Exhibit A.
Platform IP means the Platform, the Documentation, and any and all intellectual property provided to Agent, any Authorizing 211 Provider, or any Authorized User in connection with or derived from the foregoing.
Platform IP has the meaning set forth in Section 8.4(e)(ii)A.
1. 131 “[***]” means [***].
Platform IP means the MPAG Platform Know-How and the MPAG Platform Patents.
Platform IP means any and all Intellectual Property Rights relating to the Avani Software Platform, and includes Platform IP Improvements. Platform IP Improvements means any improvements in the Platform IP, including any Intellectual Property Rights discovered, developed or otherwise coming into existence in connection with the provision of the Service (other than Customer Data). Policies has the meaning given at the beginning of these Terms of Use.
Platform IP means the Platform Patents and Platform Know-How. 1.119 “Platform Know-How” means any and all Know-How that is created, conceived or developed after the Effective Date: (a) by or on behalf of either Party or (b) jointly by or on behalf of Pharming on the one hand, and by or on behalf of Orchard on the other hand, in each case (a) and (b), in performing activities under this Agreement, in each case to the extent such Know-How relates solely to the Platform. 1.120 “Platform Patents” means any Patents that Cover any Platform Know-How. 1.121 “PMDA” means Japan’s Pharmaceuticals and Medical Devices Agency and any successor agency or authority having substantially the same function. 1.122 “Pre-Clinical Budget” means the budget for the Pre-Clinical Plan (excluding any NTCR Activities) set out in the Pre-Clinical Plan. 1.123 “Pre-Clinical Plan” means the pre-clinical research plan attached hereto as Schedule 1.123. 1.124 “Pre-Clinical Research” means the activities carried out by or on behalf of a Party hereunder (whether on its own or jointly with the other Party) pursuant to the Pre-Clinical Plan. 1.125 “Pricing Approval” means, with respect to any country where a Governmental Authority authorizes reimbursement or access, or approves or determines pricing, for pharmaceutical or biologic products, receipt (or, if required to make such authorization, 23 approval of determination effective publication) of such reimbursement or access authorization or pricing approval or determination (as the case may be). 1.126 “Primary Indication” means the diagnosis, prophylaxis, treatment, palliation or cure of hereditary angioedema in humans. 1.127 “Product Specific Patent” means any Orchard Background Patent, Orchard Collaboration Patent, Orchard Conditioning Patent or Platform Patent that specifically and solely claims the composition of matter, manufacture, and/or method of use of the Licensed Product. Without limiting the foregoing: (a) the Product Specific Patent identified by Orchard and existing at the Effective Date is set out in Schedule 1.127; (b) Product Specific Patents include the Patent set out in Schedule 1.127, and all Patents that claim priority from or arise from such Patent, and (c) the Parties may choose to designate any other Orchard Background Patent, Orchard Collaboration Patent, Orchard Conditioning Patent or Platform Patent as a Product Specific Patent, subject to prior written agreement. 1.128 “Proof of Concept NTCR Endpoints” means the endpoints of th...
Platform IP means Protalix’s existing and future proprietary recombinant plant culture process and technologies directly related to such process, and improvements thereto, as may be further developed in the course [***] Omitted pursuant to a confidential treatment request. The confidential portion has been filed separately with the Securities and Exchange Commission. of the collaboration, or otherwise, by or for Protalix, at any time prior to the expiration of [***] following the First Commercial Sale of the first Licensed Product. The list of patents and patent applications included under the Platform IP, existing as of the date of execution of this Agreement is attached hereto as Annex 1.2.42 (the “Platform Patents”). All additional patent applications/ patents that may be filed by or for Protalix to cover portions of the Platform IP at any time prior to the expiration of [***] following the First Commercial Sale of the first Licensed Product, shall be immediately reported by Protalix to Teva and shall be included in the term ‘Platform Patents’ as of the time of such report.